Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 162 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergens Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms

NCT01007253
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
PL nasal spray, fluticasone furoate (FF), PL eye drops, olopatadine (OLO)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 24, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

AR101 Real-World Open-Label Extension Study

NCT03337542
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
55
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 24, 2026, 4:18 PM EDT
Completed Not applicable Interventional Results available

The Immune Directed Individualized Elimination Therapy (iDIET) Study

NCT05543512
View directory record Official record
Conditions
Eosinophilic Esophagitis, EoE
Interventions
Algorithm to diagnose food allergens, Sham diet
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 24, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Results available

Cockroach Nasal Allergen Challenge Pilot

NCT02710136
View directory record Official record
Conditions
Asthma, Cockroach Hypersensitivity
Interventions
Glycerinated German Cockroach Allergenic Extract
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 24, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

NCT02635776
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
49
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 24, 2026, 4:18 PM EDT
Completed Not applicable Interventional

Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

NCT00002031
View directory record Official record
Conditions
HIV Infections
Interventions
Dinitrochlorobenzene
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 4:18 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

NCT01534195
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 24, 2026, 4:18 PM EDT
Recruiting Phase 2 Interventional

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06686472
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 24, 2026, 4:18 PM EDT
Completed No phase listed Observational

Environmental Exposures, Genetics, and Exhaled Nitric Oxide in Pediatric Asthma

NCT00395096
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 12 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 24, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CP-481,715 Nickel Allergy Study.

NCT00141180
View directory record Official record
Conditions
Dermatitis, Allergic Contact
Interventions
CP-481,715
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
4
States / cities
Ann Arbor, Michigan • New York, New York • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2006 · Synced Oct 24, 2026, 4:18 PM EDT
Completed Phase 4 Interventional

Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit

NCT00637611
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Fexofenadine HCl
Drug
Lead sponsor
Sanofi
Industry
Eligibility
15 Years and older
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2011 · Synced Oct 24, 2026, 4:18 PM EDT
Completed No phase listed Observational

Study Evaluating Nasal Symptoms Induced by a Nasal Allergen Challenge (NAC) To House Dust Mite Allergen

NCT01936818
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Oct 24, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge

NCT01107405
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Loteprednol etabonate base (QD), Loteprednol etabonate base (BID), Loteprednol etabonate base (QID), Loteprednol etabonate suspension, Vehicle of loteprednol etabonate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Oct 24, 2026, 4:18 PM EDT
Completed No phase listed Observational

Evaluating for Contact Allergies in Patients With Chronic Urticaria

NCT00868036
View directory record Official record
Conditions
Urticaria, Patch Testing, Dermatitis, Allergy, Contact Sensitization
Interventions
Patch Testing
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 24, 2026, 4:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study to Evaluate the Efficacy of Refined Methods to Mitigate Indoor Allergens in North Carolina and Boston, Massachusetts Homes

NCT00344344
View directory record Official record
Conditions
Hypersensitivity
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 4:18 PM EDT
Not listed Phase 3 Interventional

Metal Panel Allergen Patch Test Study

NCT04500834
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Metal Panel T.R.U.E. Test
Biological
Lead sponsor
Allerderm
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 24, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

NCT05579730
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035%, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 24, 2026, 4:18 PM EDT
Withdrawn No phase listed Observational

The Metabolomics of Anaphylaxis to Immunotherapy

NCT01666288
View directory record Official record
Conditions
Anaphylaxis as a Result of Allergen or Venom Immunotherapy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 24, 2026, 4:18 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions

NCT01878929
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Allergic Conjunctivitis
Interventions
Allergen(Tree, Grass, Weeds)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
5 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
South Euclid, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 24, 2026, 4:18 PM EDT
Completed No phase listed Observational

Examining the Link Between Depression and Seasonal Allergies

NCT00770068
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 24, 2026, 4:18 PM EDT
Not listed No phase listed Observational

Healthcare Decisions on Dietary and Environmental Allergen Exposure

NCT03144908
View directory record Official record
Conditions
Dietary Allergy, Environmental Allergy
Interventions
Standard Operating Procedures
Other
Lead sponsor
Data Collection Analysis Business Management
Other
Eligibility
Not listed
Enrollment
200 participants
Timeline
2017 – 2020
U.S. locations
1
States / cities
Land O' Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 24, 2026, 4:18 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

NCT03887026
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 24, 2026, 4:18 PM EDT
Completed Not applicable Interventional

Environmental Intervention Versus Standard Care to Reduce Pharmacologic Therapy for Asthma

NCT01593111
View directory record Official record
Conditions
Asthma
Interventions
Environmental Intervention
Other
Lead sponsor
Columbia University
Other
Eligibility
6 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 24, 2026, 4:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis

NCT00868842
View directory record Official record
Conditions
Anaphylaxis
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 24, 2026, 4:18 PM EDT